Our clinical trials of tildacerfont in adults with classic CAH, CAHmelia 203 and CAHmelia 204, are open for screening | LEARN MORE


At Spruce, we are dedicated to finding new ways to treat rare endocrine disorders. Our team is focused on advancing the development of novel therapies that improve outcomes for people with classic congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS), and other rare endocrine disorders. We are led by seasoned life sciences professionals who have significant experience in developing and commercializing orphan drug therapies.

With tildacerfont, we aim to advance the treatment paradigm for classic CAH patients with a non-steroidal approach designed to offer improved disease control and reduced glucocorticoid steroid burden in patients. We also aim to develop a novel therapeutic option for women and girls suffering from a rare form of PCOS driven by adrenal dysfunction.

We are currently conducting clinical trials evaluating tildacerfont for the treatment of adults with classic CAH. We plan to initiate Phase 2 trials in pediatric classic CAH and PCOS patients in 2021.

Patients, above all else

As an innovative late-stage company, our efforts are built around the needs of patients and their loved ones. We approach our work every day with the goal of improving health outcomes and easing the disease burden for patients with rare endocrine disorders.

We listen intently to what the patient community tells us about living with conditions such as CAH, and aim to address these needs in our development programs. We have adapted our clinical trial programs to ensure the utmost safety and flexibility for participants as well as caregivers in the era of COVID-19.

To learn more about Spruce advocacy or to ask us a question, we invite patient and family caregiver advocates to connect with us at advocacy@nullsprucebiosciences.com.

Patient Resources Media Library